Good News: July 2018
- Gemstone Biotherapeutics Awarded Grant from National Science Foundation
The Baltimore-based Johns Hopkins spinout committed to developing technologies for skin regeneration was awarded a Phase I Small Business Innovation Research grant by America’s Seed Fund. The program, powered by the National Science Foundation, provides seed money to the most promising science and technology startups across the country.
- Perceptive Navigation awarded $3M in federal funding
The Johns Hopkins spinout was awarded the National Institutes of Health Phase IIB Small Business Innovation Research grant to commercialize its ultrasound system that provides medical imaging from within the body. The company will work to further develop the product and conduct studies as it works toward regulatory approval to market its device.
- Clear Guide Medical gets $2M grant to develop tools for pediatrics
The Johns Hopkins spinout has received a $2 million grant from the National Institutes of Health to apply its imaging tools to pediatrics. The company’s SCENERGY device is offered as an accessory to ultrasound systems, and helps provide imaging and guidance of a needle during medical procedures like biopsies, epidurals and tissue removal.
- Maryland companies raised $247M in venture funding during the second quarter of 2018
Investors have pumped $247 million in venture capital funding into Maryland companies in the second quarter of 2018, including Johns Hopkins startups LifeSprout and WindMIL.
- Social Innovation Lab alumni named as The Daily Record’s Very Important Professionals
The newspaper’s annual VIP List honors professionals 40 years of age and younger who have been successful in Maryland. This year’s list featured Shantell L. Roberts, of Touching Young Lives, Incorporated, and Dr. Panagis Galiatsatos, of Medicine for the Greater Good.
- Hopkins licensee Allakos Inc. announces pricing of its IPO
The clinical stage biotechnology company announced the pricing of its initial public offering of more than 7.1 million shares of its common stock at a public offering price of $18 per share. Allakos has raised more than $140M in venture funding to advance a pipeline of drug treatment candidates for various gastrointestinal diseases.